It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

Image Source: Zacks Investment Research Moderna currently has two marketed vaccines in its portfolio — the COVID-19 vaccine Spikevax and ... seeking label expansion of mResvia for use in high ...

In its fourth quarter of 2025, Moderna reported $923 million in Spikevax sales, comprised of $244 million in the United States and $679 million internationally. Spikevax generated $3.1 billion in ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology ...

Moderna recently faced significant legal challenges with five international lawsuits from Genevant Sciences and Arbutus Biopharma targeting its LNP technology used in products like Spikevax®.

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...

As proven by the success of the Spikevax COVID-19 vaccine, Moderna aims to build on this achievement by expanding into applications for influenza, cancer, and rare diseases. In recent years ...